NOVATO, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release fourth quarter and full year 2013 financial results after market close on Thursday, March 13, 2014. Raptor management will host a webcast and conference call at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (877) 870-4263 for domestic callers or (412) 317-0790 for international callers. A live webcast of the conference call will be available online from the investor relations section of the company website at www.raptorpharma.com . After the call, a webcast replay will be available on the Raptor website. A telephone replay of the call will be available by dialing (877) 344-7529 for domestic callers or (412) 317-0088 for international callers, and conference number: 10042521. About Raptor Pharmaceuticals Raptor Pharmaceutical Corp. is a global biopharmaceutical company focused on the development and commercialization of life-altering therapeutics that treat rare, debilitating and often fatal diseases. The company is engaged in multiple therapeutic areas such as nephropathic cystinosis, Huntington's disease (HD), nonalcoholic fatty liver disease, Leigh syndrome and other mitochondrial diseases. With an approved product in the U.S. and EU, Raptor also holds several orphan drug designations, including U.S. orphan drug designation for RP103 in Huntington's disease. A request for EU designation for RP103 in HD will be submitted with clinical data. For additional information, please visit www.raptorpharma.com .
CONTACT: Raptor Company Contact: Georgia Erbez Chief Financial Officer Raptor Pharmaceutical Corp. (415) 408-6231 firstname.lastname@example.org INVESTOR CONTACT: Westwicke Partners, LLC Robert H. Uhl Managing Director (858) 356-5932 email@example.com MEDIA CONTACT: Carolyn Hawley Canale Communications (619) 849-5375 firstname.lastname@example.org